Penelope Flohr

1.9k total citations
25 papers, 1.1k citations indexed

About

Penelope Flohr is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Penelope Flohr has authored 25 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 15 papers in Cancer Research and 10 papers in Oncology. Recurrent topics in Penelope Flohr's work include Prostate Cancer Treatment and Research (19 papers), Cancer Genomics and Diagnostics (12 papers) and Genetic factors in colorectal cancer (4 papers). Penelope Flohr is often cited by papers focused on Prostate Cancer Treatment and Research (19 papers), Cancer Genomics and Diagnostics (12 papers) and Genetic factors in colorectal cancer (4 papers). Penelope Flohr collaborates with scholars based in United Kingdom, United States and Spain. Penelope Flohr's co-authors include Johann S. de Bono, Gerhardt Attard, Christopher S. Cooper, Sandra E. Edwards, Gyula Kovács, David Lorente, Susana Miranda, Roberta Ferraldeschi, Daniel Nava Rodrigues and J Clark and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Penelope Flohr

24 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Penelope Flohr United Kingdom	10	771	555	439	302	89	25	1.1k
Adam Jendrisak United States	10	679 0.9×	518 0.9×	255 0.6×	510 1.7×	104 1.2×	32	988
Jessica Louw United States	9	692 0.9×	532 1.0×	249 0.6×	479 1.6×	114 1.3×	30	988
Mateus Crespo United Kingdom	17	525 0.7×	393 0.7×	399 0.9×	421 1.4×	97 1.1×	44	1.0k
Wendy Onstenk Netherlands	19	397 0.5×	456 0.8×	257 0.6×	455 1.5×	86 1.0×	25	813
John L. Silberstein United States	12	728 0.9×	323 0.6×	314 0.7×	413 1.4×	126 1.4×	16	1.0k
Bram De Laere Belgium	14	519 0.7×	438 0.8×	232 0.5×	339 1.1×	115 1.3×	35	793
Kevin Beja Canada	16	1.4k 1.8×	1.0k 1.8×	552 1.3×	545 1.8×	157 1.8×	25	1.7k
Anjana Menon United States	8	990 1.3×	495 0.9×	797 1.8×	191 0.6×	104 1.2×	13	1.4k
Victor Reuter United States	13	694 0.9×	309 0.6×	375 0.9×	163 0.5×	60 0.7×	19	1.1k
Bryce Lakely United States	13	378 0.5×	208 0.4×	295 0.7×	239 0.8×	68 0.8×	16	619

Countries citing papers authored by Penelope Flohr

Since Specialization

Citations

This map shows the geographic impact of Penelope Flohr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Penelope Flohr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Penelope Flohr more than expected).

Fields of papers citing papers by Penelope Flohr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Penelope Flohr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Penelope Flohr. The network helps show where Penelope Flohr may publish in the future.

Co-authorship network of co-authors of Penelope Flohr

This figure shows the co-authorship network connecting the top 25 collaborators of Penelope Flohr. A scholar is included among the top collaborators of Penelope Flohr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Penelope Flohr. Penelope Flohr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rescigno, Pasquale, Maria D. Fenor de la Maza, Stephanie Burnett, et al.. (2024). Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts (PERSEUS1).. Journal of Clinical Oncology. 42(4_suppl). 138–138. 1 indexed citations

Slovin, Susan F., Syed A. Hussain, Fred Saad, et al.. (2019). Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. Clinical Cancer Research. 25(15). 4624–4633. 31 indexed citations

Sumanasuriya, Semini, George Seed, Niven Mehra, et al.. (2019). Cell-free DNA as a biomarker for taxane treatment in advanced prostate cancer.. Journal of Clinical Oncology. 37(15_suppl). 5070–5070. 2 indexed citations

Lorente, David, David Olmos, Joaquı́n Mateo, et al.. (2018). Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Annals of Oncology. 29(7). 1554–1560. 72 indexed citations

Parker, Chris, Roberto Alonzi, Nina Tunariu, et al.. (2018). Radium-223: Disease response and fracture assessment by whole body diffusion-weighted MRI (WB-DWMRI) in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 36(15_suppl). 5024–5024. 2 indexed citations

Raba, Katharina, Fabienne Müller, Bianca Behrens, et al.. (2017). Analysis of DNA methylation in single circulating tumor cells. Oncogene. 36(23). 3223–3231. 68 indexed citations

Kolinsky, Michael, Pasquale Rescigno, Diletta Bianchini, et al.. (2017). A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC.. Journal of Clinical Oncology. 35(6_suppl). 135–135. 4 indexed citations

Mateo, Joaquı́n, Helen Mossop, Jane Goodall, et al.. (2017). Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial.. Journal of Clinical Oncology. 35(6_suppl). 141–141. 2 indexed citations

Mehra, Niven, Ricardo Morilla, Adam Sharp, et al.. (2016). High neutrophil-to-lymphocyte ratio (NLR), myeloid-derived suppressor cells (MDSCs) and resistance to corticosteroid therapy (CST) in castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 34(15_suppl). 5076–5076. 3 indexed citations

10.

Ahmad, Zahida, Rajiv Kumar, Berni Ebbs, et al.. (2016). Molecular characterization of PDL1 status of circulating tumor cells (CTCs) isolated with a novel label-free inertial microfluidic system from patients (pts) with advanced cancers. Annals of Oncology. 27. vi22–vi22. 3 indexed citations

11.

Kolinsky, Michael, Joaquı́n Mateo, Semini Sumanasuriya, et al.. (2016). Clinical characteristics of metastatic castration-resistant prostate cancer (mCRPC) patients with DNA repair (DNAr) defects.. Journal of Clinical Oncology. 34(15_suppl). 5028–5028. 2 indexed citations

12.

Crespo, Mateus, Guus van Dalum, Roberta Ferraldeschi, et al.. (2015). Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. British Journal of Cancer. 112(7). 1166–1174. 53 indexed citations

13.

Lorente, David, David Olmos, Joaquı́n Mateo, et al.. (2015). Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38 trials.. Journal of Clinical Oncology. 33(15_suppl). 5014–5014. 4 indexed citations

14.

Mateo, Joaquı́n, Daniel Nava Rodrigues, Penelope Flohr, et al.. (2014). A phase 1-2 study of the type I progesterone receptor (PR) antagonist onapristone (ONA) in patients (pts) with advanced castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 32(15_suppl). TPS5097–TPS5097. 2 indexed citations

15.

Ferraldeschi, Roberta, Rachel Krupa, Jessica Louw, et al.. (2014). Sequential monitoring and characterization of circulating tumor cells (CTCs) using the epic sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with recently approved therapeutics.. Journal of Clinical Oncology. 32(4_suppl). 78–78. 3 indexed citations

16.

Mateo, Joaquı́n, Michael Ong, Lorna Pope, et al.. (2012). Correlation of oncogenic mutations in circulating cell-free DNA (cfDNA) and tumor tissue through a multiplex sequencing platform in patients under consideration for phase I trials.. Journal of Clinical Oncology. 30(30_suppl). 6–6.

17.

Reid, Alison, Gerhardt Attard, Laurence Ambroisine, et al.. (2010). Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. British Journal of Cancer. 102(4). 678–684. 201 indexed citations

18.

Attard, Gerhardt, Charles Jameson, Penelope Flohr, et al.. (2008). Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity. Journal of Clinical Pathology. 62(4). 373–376. 22 indexed citations

19.

Attard, Gerhardt, J Clark, Laurence Ambroisine, et al.. (2008). Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. British Journal of Cancer. 99(2). 314–320. 79 indexed citations

20.

Clark, J, Sue Merson, Sameer Jhavar, et al.. (2006). Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 26(18). 2667–2673. 190 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact